BRITISH COLUMBIA, Canada--(BUSINESS WIRE)--InNexus Biotechnology Inc. (OTCBB:IXSBF) (TSX VENTURE:IXS), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL™) technology, today announced that Judith James, M.D., Ph.D., Lou Kerr Chair in Biomedical Research at the Oklahoma Medical Research Foundation and Professor of Medicine/Adjunct Professor of Pathology at the University of Oklahoma Health Sciences Center, has joined InNexus’ Scientific Advisory Board. Dr. James joins Dr. J. Donald Capra, President Emeritus of the Oklahoma Medical Research Foundation and InNexus Scientific Advisory Board Chairman, Dr. John D. Minna, Dr. Carlos L. Arteaga, Dr. Ellen Vitetta and Dr. Martin Weigert.
